taxanes in metastatic breast cancer - Alberta Health Services
taxanes in metastatic breast cancer - Alberta Health Services
taxanes in metastatic breast cancer - Alberta Health Services
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Figure 2: S<strong>in</strong>gle agent taxane vs. non-taxane/non-anthracycl<strong>in</strong>e: meta-analysis of overall response<br />
Study name Rate<br />
R enc<br />
al<br />
95%<br />
atio Confid e<br />
Dieras 1<br />
.000 Interv 2.534<br />
Statistic Rate ratio and 95%<br />
p-<br />
Value<br />
995 3 – 3.551 0.000<br />
Bonneterre 1997 1. 000 0.954 - 1.048 1.000<br />
Talbot 200 2 1.385 1.239<br />
– 1.547 0.000<br />
Nabholtz 1999 2 .586 2.463 – 2.716 0.000<br />
Sjostrom<br />
1999 2.000 1.913- 2.090 0.000<br />
Random Effects<br />
1.843 1.227 – 2.767<br />
0.003<br />
Table 2: Taxane/non-anthracycl<strong>in</strong>e regimen vs. s<strong>in</strong>gle agent taxane Author, year Phase Treatment arms<br />
N<br />
O’Shaughnessy, 2002 III Docetaxel + capecitab<strong>in</strong>e Docetaxel<br />
Alba<strong>in</strong>, 2004 [abstract] III Paclitaxel + gemcitab<strong>in</strong>e<br />
Paclitaxel<br />
Beslija, 2006 [abstract] II Docetaxel + capecitab<strong>in</strong>e<br />
Docetaxel to capecitab<strong>in</strong>e at<br />
progression<br />
* p-value
Change language